Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

padeliporfin 5Mitomycin 3pembrolizumab 2alectinib 2Standard of Care 2Pluvicto 2Nivolumab 2Cisplatin 2Abiraterone Acetate 2valrubicin 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1osimertinib 1onapristone 1olaparib 1gallium 68 PSMA-11 1enzalutamide 1enfortumab vedotin 1darolutamide 1cobimetinib 1apalutamide 1abiraterone 1Therapeutics 1Taxes 1Sunitinib 1Radiation Dose Hypofractionation 1Pemetrexed 1Paclitaxel 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × BAY 86-7548 × Genitourinary × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡